Imdelltra Plus Imfinzi Cut Death Risk 58% for Patients with Extensive-Stage Small Cell Lung Cancer in Interim Results

Interim phase 3 results found that adding Amgen’s Imdelltra to Imfinzi reduced the risk of death by 58% in extensive-stage small cell lung cancer, though the combination remains unapproved for maintenance treatment.